Outlook Therapeutics announced FDA approval for Lytenava, its ophthalmic bevacizumab for wet AMD, marking a significant commercial milestone. The company projects over $500 million in peak annual sales by 2030 and plans a $55 million public offering to fund its U.S. launch, indicating strong growth potential.
Outlook Therapeutics has achieved a major milestone with the FDA approval of Lytenava, the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD. This approval significantly de-risks the company's primary asset and opens up the large U.S. retina market, where bevacizumab has been used off-label for years. The company's ambitious target of over $500 million in peak annual sales by 2030, supported by a $55 million public offering for commercial launch, signals strong growth potential and a clear path to market. This development is highly positive for OTLK, as it transitions from a development-stage company to a commercial one, potentially attracting increased investor interest and driving stock appreciation in the long term, though short-term dilution from the public offering is a consideration.